Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Agenus. The associated price target remains the same with $23.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Emily Bodnar’s rating is based on the company’s steady progress in expanding global access to its botensilimab and balstilimab combination and the initiation of the pivotal BATTMAN Phase 3 study in refractory metastatic colorectal cancer. She views the growing physician-driven use through named-patient and access programs, supported by a new partnership with BAP Pharma and enhanced Medical Affairs capabilities, as building a scalable platform and generating valuable real-world data that can strengthen future regulatory filings.
She also highlights that the BATTMAN trial is structured for efficient enrollment through an extensive international trial network, with an FDA-endorsed design that should support potential U.S. approval without additional monotherapy arms. With capital and manufacturing support secured via the Zydus agreement, she believes Agenus is well positioned to execute on its late-stage strategy, justifying a Buy rating and supporting the unchanged $23 price target.
According to TipRanks, Bodnar is a 4-star analyst with an average return of 10.5% and a 37.95% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., Arcus Biosciences, and NovoCure.